U.S. Markets close in 11 mins

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7406+0.0697 (+10.39%)
As of 03:47PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6709
Bid0.7350 x 1000
Ask0.7600 x 1000
Day's Range0.6706 - 0.8300
52 Week Range0.5500 - 7.5000
Avg. Volume1,004,350
Market Cap4.726M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-1.1290
Earnings DateMar 21, 2022 - Mar 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    GeoVax Announces Upcoming Presentations at Scientific Conferences

    ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences. 2022 National Biotechnology Conference, Anaheim, CA, May 9-12 On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic P

  • GlobeNewswire

    GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

    Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2022. GeoVax’s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, April 27 to discuss f

  • Benzinga

    GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

    The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle. They are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses. GeoVax's GV-MVA-VLP vaccine platform utilizes modifie